Achieving glycemic goal with initial versus sequential combination therapy using metformin and pioglitazone in type 2 diabetes mellitus

Current Medical Research and Opinion

Volumn 27, Issue 1, 2011, Pages 189-195

  Pandya, Bhavik J ^a   Bron, Morgan ^a   McCall, Therese ^a   Yu, Andrew P ^b   Chen, Kristina S ^b   Mattson, Miles E ^b   Wu, Eric Q ^b  

^a Takeda Pharmaceuticals International Inc   (United States)

^b ANALYSIS GROUP   (United States)

Author keywords

Combination therapy; Diabetes mellitus; Metformin; Pioglitazone

Indexed keywords

HEMOGLOBIN A1C; METFORMIN; PIOGLITAZONE;

ADULT; ARTICLE; COMPARATIVE STUDY; DRUG DOSE SEQUENCE; FEMALE; GLYCEMIC CONTROL; HEMOGLOBIN DETERMINATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS;

ADULT; BLOOD GLUCOSE; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; MALE; METFORMIN; MIDDLE AGED; REGISTRIES; RETROSPECTIVE STUDIES; THIAZOLIDINEDIONES;

EID: 78650334782     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2010.536755     Document Type: Article

References (23)

1. National Diabetes Fact Sheet [article online], 2007. Available at: http:// www.cdc.gov/diabetes/pubs/pdf/ndfs-2007.pdf [Last accessed 4 November 2000]
2. Smiley D, Umpierrez G. Metformin/rosiglitazone combination pill (Avandamet) for the treatment of patients with type 2 diabetes. Expert Opin Pharmacother 2007;8:1353-64
3. Stolar MW, Hoogwerf BJ, Boyle PJ, et al. Managing type 2 diabetes: going beyond glycemic control. J Manag Care Pharm 2008;14(5 suppl B):S2-19
4. Gilmer TP, O'Connor PJ, Manning WG, et al. The cost to health plans of poor glycemic control. Diabetes Care 1997;20:1847-53
5. American Diabetes Association. Standards of medical care in diabetes - 2009. Diabetes Care 2009;32:S13-61
6. American College of Endocrinology, American Association of Clinical Endocrinologists. ACE/AACE consensus conference on the implementation of outpatient management of diabetes mellitus: consensus conference recommendations. Endocr Pract 2006;12: 6-12
7. Zhou G, Myers R, Li Y, et al. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 2001;108:1167-74
8. Smith U. Pioglitazone: mechanism of action. Int J Clin Pract Suppl 2001; 121:13-18 (Pubitemid 32916691)
9. Van Gaal LF, De Leeuw IH. Rationale and options for combination therapy in the treatment of type 2 diabetes. Diabetologia 2003;46:M44-50
10. Molavi B, Rassouli N, Bagwe S, et al. A review of thiazolidinediones and metformin in the treatment of type 2 diabetes with focus on cardiovascular complications. Vasc Health Risk Manag 2007;3:967-73
11. Hill NR, Matthews DR. Pioglitazone and metformin. Drugs of Today (Barc) 2007;43:443-54
12. Staels B. Metformin and pioglitazone: effectively treating insulin resistance. Curr Med Res Opin 2006;22:S27-37
13. Perez A, Zhao Z, Jacks R, et al. Efficacy and safety of pioglitazone/metformin fixed-dose combination therapy compared with pioglitazone and metformin monotherapy in treating patients with T2DM. Curr Med Res Opin 2009;25:2915-23
14. Kaku K. Efficacy and safety of therapy with metformin plus pioglitazone in the treatment of patients with type 2 diabetes: a double-blind, placebo-controlled, clinical trial. Curr Med Res Opin 2009;25:1111-19
15. Goldstein BJ, Feinglos MN, Lunceford JK, et al. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care 2007;30: 1979-87
16. Rosenstock J, Baron A, Camisasca RP, et al. Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetes. Diabetes Obes Metab 2007;9:175-85
17. Deeks ED, Scott LJ. Pioglitazone/metformin. Drugs 2006;66:1863-77
18. Tan MH, Glazer NB, Johns D, et al. Pioglitazone as monotherapy or in combination with sulfonylurea or metformin enhances insulin sensitivity (HOMA-S or QUICKI) in patients with type 2 diabetes. Curr Med Res Opin 2004;20:723-8
19. Charbonnel B, Schernthaner G, Brunetti P, et al. Long-term efficacy and tolerability of add-on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetes. Diabetologia 2005;48:1093-104
20. Bolli G, Dotta F, Rochotte E, et al. Efficacy and tolerability of vildagliptin vs. pioglitazone when added to metformin: a 24-week, randomized, double-blind study. Diabetes Obes Metab 2008;10:82-90
21. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992;45:613-19
22. Diabetes case shows pitfalls of treatment rules [article online], 2009. Available at: http://professional.diabetes.org/News-Display.aspx?TYP14; 9&CID14;74804 [Last accessed 2 November 2009]
23. Fonseca VA, Rosenstock J, Wang AC, et al. Colesevelam HCl improves gly-cemic control and reduces LDL cholesterol in patients with inadequately controlled type 2 diabetes on sulfonylurea-based therapy. Diabetes Care 2008;31:1479-84